Odomzo (Sonidegib)

Sonidegib, the active ingredient in Odomzo, is a Hedgehog pathway inhibitor presented as a 200 mg capsule for oral use. It is an antineoplastic agent indicated for the treatment of locally advanced basal cell carcinoma in patients unsuitable for surgery or radiation.

GNH USA supplies Odomzo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures quality and regulatory compliance across all shipments. Customers benefit from reliable delivery timelines and dedicated technical support.

Odomzo (sonidegib) targets the Hedgehog signaling pathway, which is implicated in certain skin cancers.

- Locally advanced basal cell carcinoma: reduces tumor growth in patients unsuitable for surgery or radiation.

Common Side Effects: - Muscle spasms: intermittent involuntary contractions often affecting the limbs. - Alopecia: diffuse hair thinning or loss. - Dysgeusia: altered taste perception, sometimes metallic. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Elevated creatine kinase: may indicate muscle injury. - Hepatic enzyme elevation: potential liver function impairment. - QT interval prolongation: risk of cardiac arrhythmias. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Interstitial lung disease: rare pulmonary inflammation.

Precautions for Odomzo include regular monitoring and risk mitigation: - Liver function monitoring: obtain baseline tests and repeat periodically. - Creatine kinase assessment: check levels if muscle symptoms develop. - QT interval evaluation: avoid in patients with known prolongation or concurrent QT‑prolonging drugs. - Pregnancy risk: use only if benefit outweighs potential fetal harm; employ effective contraception. - Drug interaction vigilance: avoid strong CYP3A4 inhibitors that may raise exposure. - Store at ambient temperature: keep in original container, protect from moisture.

Potential drug interactions with Odomzo are categorized as follows:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase sonidegib plasma concentrations. - Concomitant QT‑prolonging agents: heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce sonidegib effectiveness. - Antacids containing aluminum or magnesium: could affect oral absorption. - Warfarin: may require closer INR monitoring due to possible metabolic interaction.